CN103432128B - A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer - Google Patents
A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer Download PDFInfo
- Publication number
- CN103432128B CN103432128B CN201310374309.2A CN201310374309A CN103432128B CN 103432128 B CN103432128 B CN 103432128B CN 201310374309 A CN201310374309 A CN 201310374309A CN 103432128 B CN103432128 B CN 103432128B
- Authority
- CN
- China
- Prior art keywords
- pioglitazone hydrochloride
- release pellet
- pellet preparations
- compound formulation
- medicated layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A compound formulation for pioglitazone hydrochloride sustained-release pellet preparations medicated layer, assembly percentage by weight is: pioglitazone hydrochloride 60.0-98.0%, binding agent 1.0-15.0%, solubilizing agent 0.1-4.0%, and above each component by weight ratio sum is 100%; Compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations obtained by mixing with other spice, make blood sugar decreasing effect desirable, the toxic and side effects of medicine can be reduced, continual and steady blood sugar decreasing effect can be reached in vivo, be conducive to the compliance improving patient, there is higher bioavailability and stable blood drug level, effectively can improve clinical efficacy, for domestic and international diabetics provides better dosage regimen and curative effect.
Description
Technical field
The present invention relates to diabetes pharmaceutical technology sectors, especially a kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer.
Background technology
Diabetes (diabetes) be by the various virulence factor of inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors etc. act on body cause hypoinsulinism, insulin resistant etc. and cause a series of metabolism disorder syndrome such as sugar, protein, fat, water and eletrolytes.The performance such as be main feature clinically with hyperglycemia, polyuria, polydipsia, polyphagia can appear in model case, become thin, i.e. " three-many-one-little " symptom; Diabetes (blood glucose), once control badly can cause complication, cause the exhaustion pathological changes at the positions such as kidney, eye, foot, and cannot cure; Diabetes have become commonly encountered diseases and the frequently-occurring disease in China and even the world, and have become one of the highest disease of M & M.Diabetes are divided into amphitypy, and I type is insulin dependent diabetes mellitus (IDDM), and II type is non-insulin-dependent diabetes mellitus.Wherein II type non-insulin-dependent diabetes mellitus patient is in the majority, accounts for patient populations's more than 90%.
Metformin hydrochloride is a kind of biguanides oral antidiabetic drug, for the treatment of non-insulin-dependent diabetes mellitus.This medicine mainly acts on islets of langerhans and organizes outward, suppresses enterocyte to absorb glucose, increases surrounding tissue to the sensitivity of insulin, increases non-insulin and relies on gluconeogenesis function of liver.The hypoglycemic activity of biguanides does not rely on normal islet function and B cell, but increases the anerobic glycolysis of glucose, suppresses hepatic gluconeogenesis, reduces plasma glucagon level.Pioglitazone hydrochloride is Studies of The Insulin Sensitizer Thiazolidinediones medicine, and it can increase insulin sensitivity, reduces blood glucose.The competitive peroxide activator enzyme paraphyte receptor of such medicine energy, regulate transcribing of Insulin sensitivity gene, increase transcribing of peripheral tissues's Glucose transporter-1 and glucose transporter 4 etc. to synthesize with albumen, increase picked-up and the transhipment of basal glucose, thus change insulin resistant and play hypoglycemic activity.Metformin hydrochloride and pioglitazone hydrochloride can improve insulin resistant from different approaches.When pioglitazone hydrochloride and metformin hydrochloride coupling, pioglitazone improves the sensitivity of tissue to insulin, and the effect of the anerobic glycolysis and increase surrounding tissue insulin and its receptors bind that make metformin hydrochloride improve surrounding tissue better plays.The time limit of the two hypoglycemic activity supplements mutually, and curative effect superposes mutually, and side effect offsets.It is the good combination that treatment onset type Ⅱdiabetes mellitus especially improves insulin resistant.
Pellet capsule belongs to polydisperse system, each dosage is usually containing tens or a hundreds of micropill, micropill is compared with the slow-release tablet of a unit drug-supplying system, there is the features such as concise production process, drug loading are large, good fluidity, favorable reproducibility, good stability, be widely used in medicine sustained and controlled release preparation.Sustained-release micro-pill capsules preparation is developed rapidly in recent years, and domestic had the more report about slow release capsule preparation, and the Related product such as slow releasing capsule, enteric coated capsule is at commercial type.But relatively less to the research of compound sustained release capsules, the domestic listing also not ratifying compound sustained release capsules at present; The domestic existing listing of common compound tablet of metformin hydrochloride and pioglitazone hydrochloride, its compound slow-release tablet also obtained U.S. FDA approval in 2009, but there is no report to the research of compound sustained-release pellet capsule is domestic.
Number of patent application is the compound preparation that the patent document of 20101051.527.0 discloses a kind of pioglitazone hydrochloride and metformin hydrochloride double-layer osmotic pump controlled-release tablet composition, structure composition comprises from the inside to the outside successively: the label be made up of medicated layer and boosting layer, contagion gown layer, with the clothing film of drug release hole, pioglitazone hydrochloride release layer and nonessential aesthstic coat, this invention adopts double-layer osmotic pump controlled-release technology, improve the later stage release of metformin hydrochloride, but the preparation technology of existing double layer osmotic pump technology and equipment not perfect, this invention also exists the feasibility problems of suitability for industrialized production, and in double-layer osmotic pump tablet propellant add the content limiting every sheet active medicine, need to take multi-disc day and just can reach effective dose, undesirable in raising patient medication compliance.
In view of the foregoing, now invent a kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer, compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations obtained by mixing with other spice, make blood sugar decreasing effect desirable, the toxic and side effects of medicine can be reduced, continual and steady blood sugar decreasing effect can be reached in vivo, be conducive to the compliance improving patient, there is higher bioavailability and stable blood drug level, effectively can improve clinical efficacy.For domestic and international diabetics provides better dosage regimen and curative effect.
Summary of the invention
The object of the invention is to overcome deficiency of the prior art, a kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer is provided, compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations obtained by mixing with other spice, can control medicine blood drug level effectively, and blood drug level is stablized, and there is higher bioavailability, can clinical efficacy be improved, reduce medicining times, continual and steady blood sugar decreasing effect can be reached, can also compliance be improved, reduce untoward reaction.
The present invention to achieve these goals, adopt following technical scheme: a kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer, assembly percentage by weight is: pioglitazone hydrochloride 60.0-98.0%, binding agent 1.0-15.0%, solubilizing agent 0.1-4.0%, above each component by weight ratio sum is 100%;
The binding agent bought from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " wherein one or more combination "; The solubilizing agent bought from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " wherein one or more combination ".
Assembly percentage by weight is: pioglitazone hydrochloride 82.0-90.0%, hypromellose 8.0-11.0%, Polysorbate 0.5-2.0%, and above each component by weight ratio sum is 100%.
Assembly percentage by weight is: pioglitazone hydrochloride 84.0-93.0%, carboxymethyl cellulose 6.0-12.0%, sorbitan fatty acid ester 0.3-1.5%, and above each component by weight ratio sum is 100%.
The invention has the beneficial effects as follows: pioglitazone hydrochloride ordinary preparation, after oral administration, under fasting conditions, pioglitazone hydrochloride can be measured in serum after 30 minutes, within 2 hours, reach peak concentration, food can by peak concentration time retardation by 3 ~ 4 hours, and then medicine is eliminated in vivo fast, and Drug therapy window is narrower.After pioglitazone hydrochloride is prepared into slow releasing preparation, the plasma concentration of medicine can be maintained for a long time in treatment window.Can effectively control medicine blood drug level, blood drug level is stablized, and there is higher bioavailability, can clinical efficacy be improved, reduce medicining times, continual and steady blood sugar decreasing effect can be reached, can also compliance be improved, reduce untoward reaction.
Pioglitazone hydrochloride, due to indissoluble in water, so add sodium lauryl sulphate in medicated layer, can improve drug release rate and the degree of slow-release micro-pill.
Compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations obtained by mixing with other spice, make blood sugar decreasing effect desirable, the toxic and side effects of medicine can be reduced, continual and steady blood sugar decreasing effect can be reached in vivo, be conducive to the compliance improving patient, there is higher bioavailability and stable blood drug level, effectively can improve clinical efficacy, for domestic and international diabetics provides better dosage regimen and curative effect.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail:
Embodiment 1
Assembly percentage by weight is: pioglitazone hydrochloride 60.0-98.0%, binding agent 1.0-15.0%, solubilizing agent 0.1-4.0%, and above each component by weight ratio sum is 100%;
The binding agent bought from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " wherein one or more combination "; The solubilizing agent bought from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " wherein one or more combination ".
Embodiment 2
Assembly percentage by weight is: pioglitazone hydrochloride 82.0-90.0%, hypromellose 8.0-11.0%, Polysorbate 0.5-2.0%, and above each component by weight ratio sum is 100%.
Embodiment 3
Assembly percentage by weight is: pioglitazone hydrochloride 84.0-93.0%, carboxymethyl cellulose 6.0-12.0%, sorbitan fatty acid ester 0.3-1.5%, and above each component by weight ratio sum is 100%.
The present invention is not limited to above compound formulation, and the mutual assembly between spice, all in protection scope of the present invention.
Claims (3)
1. the compound formulation of a pioglitazone hydrochloride sustained-release pellet preparations medicated layer, it is characterized in that: assembly percentage by weight is: pioglitazone hydrochloride 60.0-98.0%, binding agent 1.0-15.0%, solubilizing agent 0.1-4.0%, above each component by weight ratio sum is 100%;
The binding agent bought from market is hypromellose, polyvidone, carboxymethyl cellulose, methylcellulose, ethyl cellulose, Polyethylene Glycol, sucrose solution, sodium alginate, gelatin " wherein one or more combination "; The solubilizing agent bought from market is Polysorbate, sorbitan fatty acid ester, sodium lauryl sulphate " wherein one or more combination ".
2. the compound formulation of a kind of pioglitazone hydrochloride sustained-release pellet preparations medicated layer according to claim 1, it is characterized in that: assembly percentage by weight is: pioglitazone hydrochloride 82.0-90.0%, hypromellose 8.0-11.0%, Polysorbate 0.5-2.0%, above each component by weight ratio sum is 100%.
3. the compound formulation of a kind of pioglitazone hydrochloride sustained-release pellet preparations medicated layer according to claim 1, it is characterized in that: assembly percentage by weight is: pioglitazone hydrochloride 84.0-93.0%, carboxymethyl cellulose 6.0-12.0%, sorbitan fatty acid ester 0.3-1.5%, above each component by weight ratio sum is 100%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374309.2A CN103432128B (en) | 2013-08-26 | 2013-08-26 | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374309.2A CN103432128B (en) | 2013-08-26 | 2013-08-26 | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103432128A CN103432128A (en) | 2013-12-11 |
| CN103432128B true CN103432128B (en) | 2015-11-18 |
Family
ID=49685915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310374309.2A Expired - Fee Related CN103432128B (en) | 2013-08-26 | 2013-08-26 | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103432128B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686123A (en) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Pyrolidone hydrochloride drip pill and its preparation method |
| CN1728996A (en) * | 2002-11-15 | 2006-02-01 | 兰贝克赛实验室有限公司 | Pharmaceutical compositions containing abiguanide-glitazone combination |
| CN1726912A (en) * | 2005-07-25 | 2006-02-01 | 天津药物研究院 | Slow release capsule of compound metformin pyrrolidone and preparation method |
| CN101204394A (en) * | 2007-11-23 | 2008-06-25 | 杭州华东医药集团生物工程研究所有限公司 | Composite containing pioglitazone HCL and repaglinide |
| CN101721414A (en) * | 2009-12-14 | 2010-06-09 | 杭州华东医药集团生物工程研究所有限公司 | Composition containing pioglitazone hydrochloride and metformin hydrochloride and preparation thereof |
| CN102058557A (en) * | 2009-11-18 | 2011-05-18 | 天津药物研究院 | Multicomponent sustained-release preparation and preparation method thereof |
| WO2011107855A2 (en) * | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
-
2013
- 2013-08-26 CN CN201310374309.2A patent/CN103432128B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1728996A (en) * | 2002-11-15 | 2006-02-01 | 兰贝克赛实验室有限公司 | Pharmaceutical compositions containing abiguanide-glitazone combination |
| CN1686123A (en) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Pyrolidone hydrochloride drip pill and its preparation method |
| CN1726912A (en) * | 2005-07-25 | 2006-02-01 | 天津药物研究院 | Slow release capsule of compound metformin pyrrolidone and preparation method |
| CN101204394A (en) * | 2007-11-23 | 2008-06-25 | 杭州华东医药集团生物工程研究所有限公司 | Composite containing pioglitazone HCL and repaglinide |
| CN102058557A (en) * | 2009-11-18 | 2011-05-18 | 天津药物研究院 | Multicomponent sustained-release preparation and preparation method thereof |
| CN101721414A (en) * | 2009-12-14 | 2010-06-09 | 杭州华东医药集团生物工程研究所有限公司 | Composition containing pioglitazone hydrochloride and metformin hydrochloride and preparation thereof |
| WO2011107855A2 (en) * | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
Non-Patent Citations (1)
| Title |
|---|
| 盐酸吡格列酮缓释片处方筛选及工艺研究;陈吉生等;《中国药房》;20121231;第23卷(第13期);1195-1197 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103432128A (en) | 2013-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104146976B (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| EP2205279B1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| CN101590007A (en) | A kind of metformin hydrochloride/voigelibo sugar-lowering oral preparation compositions and preparation thereof | |
| CN103417496A (en) | Method for preparing metformin hydrochloride controlled-release pellet preparation | |
| CN106727404A (en) | Diabecron sustained-release tablet and preparation method thereof | |
| CN105233300B (en) | A kind of stable vildagliptin composition and preparation method thereof | |
| JP7007300B2 (en) | New crystalline form of dapagliflozin and its manufacturing method and application | |
| CN103446063B (en) | A kind of compound formulation of compound metformin hydrochloride pioglitazone hydrochloride sustained-release pellet preparations and preparation technology | |
| WO2024109153A1 (en) | Use of ly2922470 in preparing a medicament for preventing or treating renal diseases | |
| CN102727894B (en) | A kind of pharmaceutical composition and application thereof for the treatment of diabetes and complication thereof | |
| CN103446062A (en) | Preparing method of compound metformin hydrochloride and pioglitazone hydrochloride slow-release micro-pellet preparation | |
| CN103432128B (en) | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer | |
| CN111840112A (en) | Application of carnosic acid or derivatives thereof in preparing medicine for treating diabetic complications | |
| CN106551915A (en) | Enteric-coated composition and preparation method thereof | |
| CN103432129B (en) | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations | |
| CN103417495A (en) | Method for preparing pioglitazone hydrochloride controlled-release pellet preparation slow-release layer | |
| CN102485228B (en) | Pharmaceutical composition and purpose thereof | |
| CN1985823A (en) | Slow released preparation containing metformin hydrochloride and rosiglitazone and its preparing process | |
| CN103432081A (en) | Method for compounding drug-containing pellet core of metformin hydrochloride controlled-release pellet preparation | |
| CN103462903B (en) | A kind of preparation technology of pioglitazone hydrochloride sustained-release pellet preparations | |
| CN101683340A (en) | Sustained-release preparation of compound metformin hydrochloride rosiglitazone and preparation method thereof | |
| CN102670482A (en) | Sustained release preparation of dronedarone hydrochloride | |
| CN101711762A (en) | Medicine composition for treating hypertension | |
| CN110575443A (en) | Doxofylline sustained release tablet and preparation method thereof | |
| CN103494816B (en) | A kind of pharmaceutical composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20170826 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |